ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Pharmaceuticals

Biogen and Eisai's dementia drug tie-up pays off with US approval

New treatment holds promise for Alzheimer's patients but obstacles remain

Biogen and Eisai's drug Aducanumab has been shown in clinical trials to be effective in removing amyloid beta plaques in the brain associated with Alzheimer's disease. (Source photo by Biogen/AP)

TOKYO -- A pharmaceutical alliance between Japan's Eisai and U.S.-based Biogen has succeeded in developing the world's first therapeutic drug approved for slowing the onset of Alzheimer's disease.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more